Market Cap
US$107.0m
Last Updated
2020/09/21 06:01 UTC
Data Sources
Company Financials
Executive Summary
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes, medical devices in Australia and Israel. More Details
Risk Analysis
+ 1 more risk
Snowflake Analysis
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Respiri's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KMLX.F's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
29.8%
KMLX.F
0.6%
US Medical Equipment
0.08%
US Market
1 Year Return
n/a
KMLX.F
14.8%
US Medical Equipment
12.8%
US Market
Return vs Industry: Insufficient data to determine how KMLX.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how KMLX.F performed against the US Market.
Shareholder returns
| KMLX.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 29.8% | 0.6% | 0.08% |
| 30 Day | 58.8% | 1.2% | -1.8% |
| 90 Day | n/a | 11.5% | 7.2% |
| 1 Year | n/a | 15.8%14.8% | 15.3%12.8% |
| 3 Year | n/a | 72.3%67.9% | 39.2%29.9% |
| 5 Year | n/a | 148.2%129.3% | 88.3%67.1% |
Price Volatility Vs. Market
How volatile is Respiri's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Respiri undervalued compared to its fair value and its price relative to the market?
53.36x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KMLX.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KMLX.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KMLX.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: KMLX.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KMLX.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KMLX.F is overvalued based on its PB Ratio (53.4x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Respiri forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
26.1%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of KMLX.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Respiri's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Respiri performed over the past 5 years?
-14.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KMLX.F is currently unprofitable.
Growing Profit Margin: KMLX.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KMLX.F is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare KMLX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KMLX.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: KMLX.F has a negative Return on Equity (-291.05%), as it is currently unprofitable.
Next Steps
Financial Health
How is Respiri's financial position?
Financial Position Analysis
Short Term Liabilities: KMLX.F's short term assets (A$4.4M) exceed its short term liabilities (A$2.0M).
Long Term Liabilities: KMLX.F's short term assets (A$4.4M) exceed its long term liabilities (A$128.1K).
Debt to Equity History and Analysis
Debt Level: KMLX.F's debt to equity ratio (28.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if KMLX.F's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KMLX.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: KMLX.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.1% each year.
Next Steps
Dividend
What is Respiri current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KMLX.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KMLX.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KMLX.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KMLX.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KMLX.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Marjan Mikel
0.75
Tenure
Mr. Marjan Mikel, M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer of Respiri Limited since December 2, 2019 and serves as its Executive Director since November 25, 2019. Mr. Mikel has ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Research Officer | 1.58yrs | AU$327.89k | no data | |
| Executive Chairman | 0.83yr | no data | 2.34% A$ 2.5m | |
| CEO & Director | 0.75yr | no data | 0.41% A$ 434.1k | |
| Vice-President of Business Development | 8.67yrs | no data | no data | |
| Company Secretary | 1.5yrs | no data | no data | |
| Medical & Scientific Advisor | no data | AU$310.61k | no data | |
| Medical & Scientific Advisor | no data | no data | no data |
1.5yrs
Average Tenure
Experienced Management: KMLX.F's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 0.83yr | no data | 2.34% A$ 2.5m | |
| CEO & Director | 0.75yr | no data | 0.41% A$ 434.1k | |
| Non-Executive Director | 0.58yr | AU$4.17k | 0.11% A$ 122.4k | |
| Chairman of the Medical & Scientific Advisory Board | no data | AU$73.76k | no data |
0.8yrs
Average Tenure
Experienced Board: KMLX.F's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.6%.
Top Shareholders
Company Information
Respiri Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Respiri Limited
- Ticker: KMLX.F
- Exchange: OTCPK
- Founded:
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$146.636m
- Listing Market Cap: AU$107.026m
- Shares outstanding: 651.71m
- Website: https://www.respiri.co
Location
- Respiri Limited
- 432 St Kilda Road
- Suite 1
- Melbourne
- Victoria
- 3004
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RSH | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Nov 2006 |
| KMLX.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Nov 2006 |
| RSH | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Nov 2006 |
Biography
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes, medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/21 06:01 |
| End of Day Share Price | 2020/09/15 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.